Options traders have spent four consecutive sessions building put protection on KEYS. The put-call ratio has climbed from 0.75 to 0.97 since June 22 — now 2.1 standard deviations above its 20-day mean and at its highest level in over two years.
The timing is notable. The PCR spike follows a strong earnings-driven run that lifted the stock roughly 4% over the past month. Traders appear to be hedging recent gains rather than initiating fresh bearish bets.
Short interest has moved in the same direction, though from a low base. Borrowed shares jumped 37% in a single week to 1.76% of free float — still a modest absolute level, but the pace of the increase stands out. The spike occurred even as the borrow market remains extremely loose: availability sits at 7,524% relative to current short positions, meaning shares to borrow are plentiful and the cost to borrow has actually eased to 0.33%.
That combination — rising short interest alongside falling borrow cost — points to new shorts entering at favorable terms, not a squeeze or borrow-driven squeeze risk.
The defensive options positioning runs against the prevailing analyst view. In late May, eight major firms raised price targets on KEYS following quarterly results. JP Morgan lifted its target to $390. Citigroup went to $396. UBS moved to $420. The consensus mean target sits at $383 — roughly 6% above the current price of $360.
Only Morgan Stanley holds a neutral stance, with a $350 target fractionally below the current price.
Three signals now point in the same cautious direction — rising puts, rising short interest, and a stock that pulled back 5.6% in a single session on June 25 before partly recovering. Against that, the borrow market is wide open and analysts are broadly bullish. The next earnings date is August 18. How the PCR behaves into that event will indicate whether options demand is short-term hedging or something more structural.
Data summary
See the live data behind this article on ORTEX.
Open KEYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
